408 related articles for article (PubMed ID: 10800406)
1. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
Zmuda K; Neofotistos D; Ts'ao CH
Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
[TBL] [Abstract][Full Text] [Related]
2. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays.
Coppell JA; Thalheimer U; Zambruni A; Triantos CK; Riddell AF; Burroughs AK; Perry DJ
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):97-104. PubMed ID: 16479191
[TBL] [Abstract][Full Text] [Related]
3. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.
Burgess JK; Chong BH
Eur J Haematol; 1997 Apr; 58(4):279-85. PubMed ID: 9186540
[TBL] [Abstract][Full Text] [Related]
4. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
5. The effects of glycosaminoglycans on coagulation: a thromboelastographic study.
Senzolo M; Coppell J; Cholongitas E; Riddell A; Triantos CK; Perry D; Burroughs AK
Blood Coagul Fibrinolysis; 2007 Apr; 18(3):227-36. PubMed ID: 17413758
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.
Gitlin SD; Deeb GM; Yann C; Schmaier AH
J Vasc Surg; 1998 Mar; 27(3):568-75. PubMed ID: 9546248
[TBL] [Abstract][Full Text] [Related]
7. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
Fernández JA; Petäjä J; Griffin JH
Thromb Haemost; 1999 Nov; 82(5):1462-8. PubMed ID: 10595639
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay.
Tuman KJ; McCarthy RJ; Djuric M; Rizzo V; Ivankovich AD
J Cardiothorac Vasc Anesth; 1994 Apr; 8(2):144-9. PubMed ID: 8204806
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.
Castro-López V; Harris LF; O'Donnell JS; Killard AJ
Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772
[TBL] [Abstract][Full Text] [Related]
10. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
Polkinghorne KR; McMahon LP; Becker GJ
Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
[TBL] [Abstract][Full Text] [Related]
12. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study.
Grassegger A; Fritsch P; Reider N
Dermatol Surg; 2001 Jan; 27(1):47-52. PubMed ID: 11231243
[TBL] [Abstract][Full Text] [Related]
13. Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors.
Hacker UT; Gerner FM; Büning H; Hutter M; Reichenspurner H; Stangl M; Hallek M
Gene Ther; 2001 Jun; 8(12):966-8. PubMed ID: 11426338
[TBL] [Abstract][Full Text] [Related]
14. Heparinase-modified thromboelastography in cats.
Cuq B; Dunn ME; Bédard C
J Vet Emerg Crit Care (San Antonio); 2017 Jan; 27(1):127-130. PubMed ID: 28002635
[TBL] [Abstract][Full Text] [Related]
15. Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography.
Chung J; Stevic I; Gantioqui J; Atkinson H; Chan AKC; Chan HHW
Blood Coagul Fibrinolysis; 2021 Jul; 32(5):305-311. PubMed ID: 34231501
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
Ofosu FA
Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparins and heparinoids.
Eikelboom JW; Hankey GJ
Med J Aust; 2002 Oct; 177(7):379-83. PubMed ID: 12358583
[TBL] [Abstract][Full Text] [Related]
18. Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins.
Harris LF; Castro-López V; Hammadi N; O'Donnell JS; Killard AJ
Talanta; 2010 Jun; 81(4-5):1725-30. PubMed ID: 20441964
[TBL] [Abstract][Full Text] [Related]
19. Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans.
van Barlingen HH; van Beek A; Erkelens DW; de Bruin TW
J Intern Med; 1997 Aug; 242(2):125-9. PubMed ID: 9279289
[TBL] [Abstract][Full Text] [Related]
20. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
